The following tables set forth information about the Company’s reportable segments, along with the items necessary to reconcile the segment information to the totals reported in the Company’s unaudited condensed consolidated statements of operations as follows (in thousands):


	For the Three Months Ended March 31, 2026
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	3,171,349	$	—	$	3,171,349
Services revenue		—		442,372		442,372
Cost of drugs		2,672,793		—		2,672,793
Cost of services		—		260,924		260,924
Other direct costs (1)		197,782		—		197,782
Segment selling, general, and administrative expenses (2)		157,034		122,422		279,456
Segment depreciation and amortization expense (3)		25,328		6,954		32,282
Segment EBITDA	$	169,068	$	65,980	$	235,048


	For the Three Months Ended March 31, 2025
	Pharmacy Solutions		Provider Services		Total Segments
Products revenue	$	2,532,171	$	—	$	2,532,171
Services revenue		—		345,958		345,958
Cost of drugs		2,147,576		—		2,147,576
Cost of services		—		211,545		211,545
Other direct costs (1)		180,639		—		180,639
Segment selling, general, and administrative expenses (2)		115,738		90,102		205,840
Segment depreciation and amortization expense (3)		27,508		6,769		34,277
Segment EBITDA	$	115,726	$	51,080	$	166,806

(1)

Other direct costs primarily includes direct labor costs, delivery costs, insurance, and depreciation and amortization expense that relates to revenue-generating assets.

(2)

Segment selling, general, and administrative expense includes indirect labor costs, depreciation and amortization, insurance, rent, lease, supplies, professional services, maintenance, repairs, utilities, and communications expense.

(3)

Total segment depreciation and amortization expense is presented in other direct costs, costs of services, and segment general and administrative expenses, based on the associated asset.


	For the Three Months Ended
	March 31,
	2026		2025
Reconciliation of income:
Total Segment EBITDA	$	235,048	$	166,806
Segment depreciation and amortization		32,282		34,277
Expenses not allocated at segment level:
Selling, general, and administrative expenses		74,505		75,235
Depreciation and amortization		6,812		6,555
Interest expense, net		38,615		41,763
Income tax expense (benefit)		8,551		(240	)
Net income from continuing operations	$	74,283	$	9,216